With one easy blood test, Molecular You measures over 250 biomarkers, enabling more powerful and comprehensive insights for preventive and precision medicine

 Molecular You, a leader in molecular medicine and preventive health, announced the closing of a $5 million USD Series A financing, led by Voloridge Health, LLC, with participation from Dynamic Leap and others.

Health Technology Insights: Alpha Aesthetics Grows with New Clinic in Bonita Springs

With a single blood sample, Molecular You’s predictive health platform measures over 250 biomarkers across all major systems, analyzing deep biological pathways to identify health risks at their root cause, providing a comprehensive snapshot of full-body health for over 25 health areas. With this data, Molecular You delivers highly personalized, actionable lifestyle recommendations, enabling proven, preventative lifestyle actions to be taken before disease symptoms appear. This differs from traditional diagnostics taken after a patient becomes symptomatic, which often require multiple blood draws for individual tests.

This financing follows a series of key achievements for Molecular You, including:

  • Nationwide launches in both Canada and the United States in both clinical practices and direct-to-consumer online.
  • A major partnership with HealthQuest Esoterics, a full-service reference laboratory, to run the company’s current assay as a Lab Developed Test (LDT), making it eligible for reimbursement.
  • Planned near-term introduction of its next-generation multi-omic assay, which will measure over 800 biomarkers. This will enable higher-resolution analysis and broaden the platform’s scope to additional areas, including certain cancers.

Health Technology Insights: Canary Speech Names Dr. Kang Hsu Jr. as Chief Medical Officer

“We plan to use this capital to grow our customer base across both consumer and clinical channels in North America, while also continuing to expand the platform’s analysis and predictive capabilities,” said Jim Kean, CEO of Molecular You, who has decades of expertise pioneering within the health testing space, including previously founding WellnessFX and architecting the technology underlying WebMD’s consumer platform.

“We’re bringing scientific discipline and clinical-grade rigor to the booming consumer wellness sector and delivering brand new tools to enhance what clinical practices can provide,” said Dr. Murdoc Khaleghi, Chief Medical Officer at Molecular You. “Fragmented measurement of individual biomarkers cannot offer the same predictive capabilities as our platform, which sees the body as a whole. This is critical for predictive and preventative medicine, particularly for complex conditions like Alzheimer’s, PCOS, and autoimmune diseases, which are correlated to multiple individual biomarkers that are typically measured separately.”

Molecular You has previously demonstrated its ability to predict disease with the rare and accurate detection of stage 1 pancreatic cancer in a symptom-free 60-year-old woman, enabling early surgical intervention without the need for additional treatment. The patient continues to thrive and live a full and healthy life.

Investment in the longevity sector more than doubled between 2023 and 2024, reaching US$8.5 billion, according to a 2024 report from Longevity Technology.

“Molecular You is advancing a critical shift in healthcare, from reactive treatment to predictive and preventive care, through biomarker science and real-world clinical impact,” said David Vogel, CEO of Voloridge Health. “Their unique multi-omic platform integrates proteomics and metabolomics in a way that sets a new standard for precision health. This aligns with our mission to leverage data science for better health outcomes, and we believe Molecular You is well-positioned to transform how individuals and providers detect and manage disease risk at scale.”

Health Technology Insights: FDA Approves BRINSUPRI for Non-Cystic Fibrosis Bronchiectasis Treatment

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source- PR Newswire